GlassScriptPhysician profile
Renee A Debose
NPI 1780772897
$6,609.30
in general payments reported to CMS, 2019-2025
30 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $306 · 2021: $888 · 2022: $820 · 2023: $616 · 2024: $1,145 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.28 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $946.97 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $655.15 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.34 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $504.73 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $419.58 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $269.16 | 2024-2025 | Resmetirom, Rezdiffra |
| Janssen Scientific Affairs, LLC | $248.39 | 2019 | |
| Allergan, INC. | $184.04 | 2019-2020 | |
| Novo Nordisk INC | $168.36 | 2025 | Wegovy |
| Ardelyx, INC. | $155.06 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $137.75 | 2019-2022 | |
| Shionogi INC | $97.14 | 2019-2020 | |
| Conmed Corporation | $89.43 | 2025 | Conmed Biliary |
| Aimmune Therapeutics, INC. | $86.30 | 2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $82.45 | 2025 | Hemospray |
| Regeneron Healthcare Solutions, INC. | $75.63 | 2023-2025 | Dupixent |
| Celgene Corporation | $74.48 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $71.11 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $66.53 | 2019-2024 | Linzess |
| Olympus America INC. | $51.52 | 2021-2023 | Long Clip, Olympus Endotherapy Inflation Device For Endoscopic Balloon Dilation |
| Merck Sharp & Dohme LLC | $50.14 | 2022-2023 | Dificid, Zerbaxa |
| Janssen Pharmaceuticals, INC | $43.73 | 2025 | Tremfya |
| Pfizer INC. | $30.97 | 2024-2025 | |
| Gilead Sciences, INC. | $24.59 | 2023 | |
| Intra-Sana Laboratories | $22.27 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pentax of America, INC. | $22.14 | 2023 | C2 Cryoballoon |
| Alfasigma USA, INC. | $21.48 | 2020 | |
| Braintree Laboratories, INC. | $17.11 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.47 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Debose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.